Pharvaris (PHVS)
32.99
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 Pharvaris N.V. For: Sep 22 Filed by: Lu Peng
September 24, 2026 4:03 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 22 Filed by: Schikan Johannes Gerardus Christiaan Petrus
September 24, 2026 10:43 AM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Monges Viviane
September 23, 2026 4:24 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 21 Filed by: Nassif David W.
September 23, 2026 10:06 AM - SEC Filing
Form 144/A Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus
September 22, 2026 4:19 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus
September 22, 2026 4:14 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 17 Filed by: Lu Peng
September 21, 2026 4:21 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 17 Filed by: Schikan Johannes Gerardus Christiaan Petrus
September 21, 2026 4:19 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Nassif David W.
September 21, 2026 4:06 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 17 Filed by: Bjork Elisabeth
September 21, 2026 3:21 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 17 Filed by: Glassman Robert
September 21, 2026 3:17 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 17 Filed by: Lesage Anne
September 21, 2026 3:14 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 17 Filed by: Modig Berndt
September 21, 2026 3:11 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lu Peng
September 17, 2026 7:25 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus
September 17, 2026 5:28 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Modig Berndt
September 17, 2026 5:27 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Bjork Elisabeth
September 17, 2026 4:45 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
September 17, 2026 4:28 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Glassman Robert
September 17, 2026 4:20 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 15 Filed by: Abele Stefan Andreas
September 17, 2026 1:22 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 15 Filed by: Glassman Robert
September 17, 2026 9:18 AM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 14 Filed by: Souverijns Wim
September 16, 2026 2:07 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Abele Stefan Andreas
September 15, 2026 6:06 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Glassman Robert
September 15, 2026 4:44 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 11 Filed by: Lu Peng
September 15, 2026 2:30 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 14 Filed by: Modig Berndt
September 15, 2026 2:15 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Souverijns Wim
September 14, 2026 6:26 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Modig Berndt
September 14, 2026 4:49 PM - SEC Filing
Form 4 Pharvaris N.V. For: Sep 10 Filed by: Lesage Anne
September 14, 2026 12:30 PM - SEC Filing
Cantor Fitzgerald Reiterates Overweight Rating on Pharvaris B.V. (PHVS)
September 14, 2026 9:57 AM - StreetInsider
Form 4 Pharvaris N.V. For: Sep 09 Filed by: Glassman Robert
September 11, 2026 12:25 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
September 10, 2026 4:49 PM - SEC Filing
Pharvaris B.V. (PHVS) PT Raised to $44 at Guggenheim
September 10, 2026 7:06 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $62 at Morgan Stanley
September 9, 2026 7:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)
September 9, 2026 7:27 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $62 at RBC Capital
September 9, 2026 7:23 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $65 at Wells Fargo
September 9, 2026 5:50 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $79 at Citizens on Agent Trial Success
September 9, 2026 4:12 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer
September 8, 2026 2:47 PM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $65 at Cantor Fitzgerald
September 8, 2026 10:43 AM - StreetInsider
Pharvaris HAE drug hits 83% attack rate cut in phase 3 trial
September 8, 2026 6:50 AM - StreetInsider
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
September 8, 2026 6:50 AM - StreetInsider
Pharvaris presents deucrictibant data at Bradykinin Symposium 2026
September 3, 2026 6:51 AM - StreetInsider
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 3, 2026 6:50 AM - StreetInsider
Form 4 Pharvaris N.V. For: Aug 14 Filed by: Modig Berndt
August 18, 2026 11:50 AM - SEC Filing
Form SCHEDULE 13G/A Pharvaris N.V. Filed by: GENERAL ATLANTIC, L.P.
August 14, 2026 8:52 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Modig Berndt
August 14, 2026 4:38 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)
August 14, 2026 6:46 AM - StreetInsider
Form 4 Pharvaris N.V. For: Aug 11 Filed by: Lu Peng
August 13, 2026 4:37 PM - SEC Filing
Pharvaris B.V. (PHVS) PT Raised to $52 as RBC Capital Sees Upside
August 13, 2026 7:29 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $40 at Guggenheim
August 13, 2026 6:43 AM - StreetInsider
Pharvaris B.V. (PHVS) PT Raised to $75 at Citizens: Has Cash Runway Into 2028
August 13, 2026 4:04 AM - StreetInsider
Form 6-K Pharvaris N.V. For: Jun 30
August 12, 2026 6:51 AM - SEC Filing
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026 6:50 AM - StreetInsider
Pharvaris publishes AAE-C1INH disease burden study in Frontiers in Immunology
August 6, 2026 6:51 AM - StreetInsider
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
August 6, 2026 6:50 AM - StreetInsider
Form SCHEDULE 13G/A Pharvaris N.V. Filed by: LSP V Cooperatieve U.A.
July 31, 2026 7:23 AM - SEC Filing
Pharvaris publishes review on bradykinin B2 receptor as therapy target
July 22, 2026 6:50 AM - StreetInsider
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
July 22, 2026 6:50 AM - Globe NewsWire
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
July 22, 2026 6:50 AM - StreetInsider
Form 4 Pharvaris N.V. For: Jul 13 Filed by: Modig Berndt
July 15, 2026 1:08 PM - SEC Filing
Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight
July 15, 2026 5:11 AM - StreetInsider
Form 4 Pharvaris N.V. For: Jul 11 Filed by: Lu Peng
July 14, 2026 3:47 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Modig Berndt
July 13, 2026 4:39 PM - SEC Filing
FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant
July 6, 2026 6:50 AM - StreetInsider
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 6, 2026 6:50 AM - StreetInsider
Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus
July 1, 2026 7:06 PM - SEC Filing
Form 4 Pharvaris N.V. For: Jun 29 Filed by: Lesage Anne
July 1, 2026 7:03 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
June 30, 2026 4:37 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
June 30, 2026 4:37 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus
June 30, 2026 4:36 PM - SEC Filing
Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lesage Anne
June 29, 2026 6:41 PM - SEC Filing
Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus
June 29, 2026 6:18 PM - SEC Filing
Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lu Peng
June 29, 2026 6:18 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus
June 29, 2026 4:49 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
June 29, 2026 4:46 PM - SEC Filing
Form 144 Pharvaris N.V. Filed by: Lesage Anne
June 29, 2026 4:46 PM - SEC Filing
Full Article List
